Impact of Drug Price Revisions, Healthcare Policy, and Changes in Laws and Regulations
First written in FY2016. 14 of 33 entries say "Restated". Latest entry: FY2026.
Zeria Pharmaceutical moved to the "Worse" side of this theme in 2018, 2 years before the typical company in this theme (2020).
The whole theme swung hardest in 2018: 21 of 66 companies on the "Worse" side.
14 other companies' latest entry also says "Worsened".
- FY2026WorsenedAnnual report
「The business environment is becoming increasingly challenging as measures to contain healthcare expenditure, including annual NHI drug price revisions and the designated medical care benefit system for long-listed products, are being pursued.」
It has been explained that, in addition to annual NHI drug price revisions, the designated medical care benefit system for long-listed products has been added as a measure to contain healthcare expenditure, making the environment for domestic prescription drugs increasingly challenging. - FY2026-H1MaterialisedAnnual report
「The domestic market remained challenging due to drug price revisions, the selective reimbursement system for long-listed products and the impact of competing products, among other factors.」
The NHI drug price revision and the designated medical care benefit system for long-listed products introduced in October 2024 have appeared during the current interim period as challenging conditions in the domestic prescription drug market. - FY2025WorsenedAnnual report
「In the pharmaceutical industry, the business environment for prescription drugs is becoming increasingly challenging as measures to contain healthcare expenditure, including annual NHI drug price revisions, are being pursued and the designated medical care benefit system for long-listed products was introduced in October 2024.」
It states that, in addition to annual NHI drug price revisions, the designated medical care benefit system for long-listed products was introduced in October 2024, making the environment surrounding prescription drugs increasingly challenging. - FY2025-H1MaterialisedAnnual report
「Asacol, the Company's core ulcerative colitis treatment, struggled in the Japanese market due in part to the impact of the NHI drug price revision implemented in April 2024. However, overall sales increased, partly because the product performed well in the Nordic countries and elsewhere in overseas markets, and because of the effect of foreign exchange rates.」
The impact of the April 2024 NHI drug price revision actually appeared as difficulties in the Asacol domestic market. - FY2024MaterialisedAnnual report
「Asacol, the Company's core ulcerative colitis treatment, struggled in the Japanese market partly because of the NHI drug price revision and competing products. However, overall sales increased, partly because the high-dose formulation Asacol 1600 mg tablets performed well in the UK and elsewhere, supported by growth in overseas markets, and because of the effect of foreign exchange rates.」
The effects of the NHI drug price revision and competing products again appeared as difficulties in the Asacol domestic market during the fiscal year. - FY2024-Q1MaterialisedAnnual report
「Asacol, the Company's core ulcerative colitis treatment, struggled in the Japanese market due in part to the impact of the NHI drug price revision implemented in April 2023. However, sales remained firm overall as the product performed well in the UK and elsewhere, supported by growth in the 1600 mg formulation in overseas markets.」
The impact of the April 2023 NHI drug price revision actually appeared as difficulties in the Asacol domestic market. - FY2023WorsenedAnnual report
「For prescription drugs, measures to contain healthcare expenditure, including reviews of the NHI drug pricing system and the promotion of generic drug use, are being pursued more vigorously than before, and growth in the Japanese market is considered inevitably likely to slow.」
It indicates that reviews of the NHI drug pricing system and the promotion of generic drug use have intensified, making a slowdown in growth in the Japanese market inevitable. - FY2023-Q3RestatedAnnual report
「During the nine months ended the third quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It is stated that there were no new occurrences or material changes in the principal risks, including the impact of drug price revisions, healthcare policy, and regulatory changes. - FY2023-Q2RestatedAnnual report
「During the six months ended the second quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It is stated that there were no new occurrences or material changes in the principal risks, including the impact of drug price revisions, healthcare policy, and regulatory changes. - FY2023-Q1RestatedAnnual report
「During the three months ended the first quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It is stated that there were no new occurrences or material changes in the principal risks, including the impact of drug price revisions, healthcare policy, and regulatory changes. - FY2022-Q3RestatedAnnual report
「During the nine months ended the third quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It has been explained that there have been no new occurrences or material changes in the principal risks, including the effects of NHI drug price revisions, healthcare policy and changes in laws and regulations. - FY2022-Q2RestatedAnnual report
「During the six months ended the second quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It has been explained that there have been no new occurrences or material changes in the principal risks, including the effects of NHI drug price revisions, healthcare policy and changes in laws and regulations. - FY2022-Q1MaterialisedAnnual report
「In the Japanese market, sales of Asacol, the Company's core ulcerative colitis treatment, were slightly below the same quarter of the previous year due to the impact of the interim NHI drug price revision implemented in April 2021.」
The impact of the April 2021 interim NHI drug price revision actually appeared as a year-on-year decline in Asacol's domestic sales. - FY2021-Q2RestatedAnnual report
「In the Japanese market, sales of Asacol, the Company's core ulcerative colitis treatment, were affected by competing products and generics, as well as by two NHI drug price revisions in October 2019 and April 2020. However, sales exceeded the same quarter of the previous year, partly because the Company ended its sales partnership with Kyowa Kirin Co.,Ltd. at the end of March 2020 and began selling the product independently from April 2020.」
Although the effects of NHI drug price revisions and competing products and generics continue, domestic Asacol sales exceeded the same quarter of the previous year due in part to the transition to independent sales. - FY2021-Q1MaterialisedAnnual report
「In the Japanese market, sales of Asacol, the Company's core ulcerative colitis treatment, were slightly below the same quarter of the previous year following two NHI drug price revisions, in October 2019 and April 2020.」
The two NHI drug price revisions in October 2019 and April 2020 actually appeared as a year-on-year decline in Asacol's domestic sales. - FY2020MaterialisedAnnual report
「Prescription drugs underwent two NHI drug price revisions within a short period, in October 2019 and April 2020, as well as」
Two NHI drug price revisions were implemented within a short period, in October 2019 and April 2020, and the risk of drug price revisions and changes in healthcare policy materialized. - FY2020-Q3MaterialisedAnnual report
「For prescription pharmaceuticals, drug prices were revised in October 2019 following the consumption tax increase, while the use of generic drugs continued to be strongly promoted as part of measures to contain healthcare costs.」
A drug price revision was implemented in October 2019 in connection with the consumption tax increase, and risk factors related to drug price revisions and healthcare cost-containment policies actually materialized. - FY2020-Q2RestatedAnnual report
「During the six months ended the second quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It is stated that there were no new occurrences or material changes in the principal risks, including the impact of drug price revisions, healthcare policy, and regulatory changes. - FY2020-Q1RestatedAnnual report
「The pharmaceutical industry remained in a difficult environment. The use of generic drugs for prescription pharmaceuticals continued to be strongly promoted as part of measures to contain medical costs, while the OTC pharmaceutical market continued to face intensifying competition.」
The promotion of generic drug use and intensifying competition in the OTC pharmaceutical market are described as continuing factors behind the difficult business environment. - FY2019WorsenedAnnual report
「Measures to contain healthcare costs, including a fundamental overhaul of the drug pricing system and the promotion of generic drug use, are being pursued more vigorously than before, and growth in the domestic market is expected inevitably to slow in the future.」
It explicitly states that slower growth in the domestic market is inevitable due to the fundamental review of the drug pricing system and the promotion of generic drug use. - FY2019-Q3RestatedAnnual report
「The pharmaceutical industry remained in a difficult environment. Prescription pharmaceuticals were subject to unexpected drug price reductions resulting from fundamental reform of the drug pricing system in April of the previous year, while measures to contain medical costs, including the promotion of generic drug use, were strongly pursued. The OTC pharmaceutical market also continued to face intensifying competition.」
Healthcare policy and regulatory factors, including drug price reductions resulting from a fundamental reform of the drug pricing system and the promotion of generic drug use, continue to affect the business environment. - FY2019-Q2RestatedAnnual report
「The pharmaceutical industry remained in a difficult environment. Prescription pharmaceuticals were subject to unexpected drug price reductions resulting from fundamental reform of the drug pricing system in April, while measures to contain medical costs, including the promotion of generic drug use, were strongly pursued. The OTC pharmaceutical market also continued to face intensifying competition.」
Healthcare policy and regulatory factors, including drug price reductions resulting from a fundamental reform of the drug pricing system and the promotion of generic drug use, continue to affect the business environment. - FY2019-Q1WorsenedAnnual report
「Asacol, the Company's core treatment for ulcerative colitis, struggled both in Japan, due to the drug price revision in April this year and the impact of generic and competing products, and overseas, due to declining sales in certain regions and the appreciation of the Swiss franc.」
The impact of the drug price revision appeared as difficulties in Asacol's domestic sales, while overseas sales also declined and were affected by foreign exchange movements. - FY2018WorsenedAnnual report
「Measures to contain healthcare costs, including a fundamental overhaul of the drug pricing system and the promotion of generic drug use, are being pursued more vigorously than before, and growth in the domestic market is expected inevitably to slow in the future.」
The review of the drug pricing system is described as "fundamental," and the outlook for greater generic drug use and slower domestic market growth is explicitly stated. - FY2018-Q3WorsenedAnnual report
「The pharmaceutical industry remained in a difficult environment. Prescription pharmaceuticals faced strong measures to contain healthcare costs, including a major overhaul of the drug pricing system and the promotion of generic drug use, while competition in the OTC pharmaceutical market continued to intensify.」
The drug pricing system is described as undergoing a "major overhaul," with strong measures to contain healthcare costs and promote generic drug use. - FY2018-Q2RestatedAnnual report
「The pharmaceutical industry remained in a difficult environment. The use of generic drugs for prescription pharmaceuticals continued to be strongly promoted as part of measures to contain medical costs, while the OTC pharmaceutical market continued to face intensifying competition.」
Measures to contain healthcare costs, the promotion of generic drug use, and competition in the OTC market continue to be described as business-environment factors. - FY2017RestatedAnnual report
「National governments set reimbursement prices for prescription pharmaceuticals. Reimbursement prices are generally reduced through price revisions conducted once every 2 years.」
The impact of drug price revisions, healthcare policy, and regulatory changes on sales volumes and profit continues to be described. - FY2017-Q3RestatedAnnual report
「Asacol, the Company's core treatment for ulcerative colitis, continued to perform steadily overseas but struggled in Japan due to the drug price revision in April of the previous year and the impact of generic drugs.」
The difficulties in Asacol's domestic sales caused by the drug price revision and generic drugs continue to be described. - FY2017-Q2RestatedAnnual report
「Asacol, the Company's core treatment for ulcerative colitis, continued to perform steadily overseas but struggled in Japan due to the drug price revision in April this year and the impact of generic drugs.」
The difficulties in Asacol's domestic sales caused by the drug price revision and generic drugs have continued. - FY2017-Q1MaterialisedAnnual report
「Asacol, the Company's core treatment for ulcerative colitis, struggled in Japan due to the drug price revision in April this year and the impact of generic drugs.」
The impact of the drug price revision and generic drugs actually appeared in Asacol's domestic sales. - FY2016First statedAnnual report
「National governments set reimbursement prices for prescription pharmaceuticals. Reimbursement prices are generally reduced through price revisions conducted once every 2 years.」
The impact of the frequency of drug price revisions, sales volumes, and new drug development and launches is described.